fda approvals for daratumumab and osimertinib, regulatory advances in rcc and cll, and more
Published 8 years ago • 294 plays • Length 7:44
Download video MP4
Download video MP3
Similar videos
-
6:27
fda approval in nsclc, and ema regulatory advances in pancreatic cancer, nhl, and cll
-
6:56
fda approves tas-102, nivolumab breakthrough in rcc, two priority reviews, and more
-
3:14
dr. west on fda approval of frontline osimertinib in egfr nsclc
-
1:34
fda approval of frontline nivolumab/ipilimumab combo in rcc
-
1:40
dr. powles on fda approval of pembrolizumab plus axitinib in advanced rcc
-
1:52
dr. goldberg discusses osimertinib in nsclc
-
9:10
fda approvals in urothelial cancer and gist, promising data in urothelial carcinoma, and more
-
2:11
dr. low on osimertinib versus dacomitinib in egfr-mutant nsclc
-
1:40
dr. ramalingam on the role of osimertinib in egfr t790m-positive advanced nsclc
-
10:01
fda approvals in sclc and a biosimilar, and japanese approvals in aml, ntrk tumors, and more
-
0:52
dr. mckay on fda approval of nivolumab/ipilimumab in frontline rcc
-
2:02
dr. mcgregor on implications of the fda approval of pembrolizumab/axitinib in rcc
-
2:04
dr. suresh ramalingam on frontline osimertinib data in egfr nsclc
-
3:19
fda approval of durvalumab for advanced bladder cancer
-
7:00
flaura trial: impact of os data in advanced nsclc
-
7:45
upfront use of osimertinib in egfr nsclc
-
1:22
copy of dr. mcgregor on implications of the fda approval of pembrolizumab/axitinib in rcc
-
6:06
renal tumors additional questions
-
1:49
fda approval of durvalumab for bladder cancer
Clip.africa.com - Privacy-policy